Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | Chief Medical Officer | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,632 |
Reported balance
After 2026-09-04 transaction · row 1
1 source rowRow 1 · 2026-09-04 · Grant · Acquired 52,632 · Balance 52,632 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.16 · Expires 2036-09-04 | Direct | 88,254 |
Reported balance
After 2026-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-04 · Grant · Acquired 88,254 · Balance 88,254 F2: 1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2: 1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 9, 2026 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 88,254 | $0.00 Strike: $61.16 | $0.00 |
DisclosureSEC source: 0002151661-26-000004 · wk-form4_1788990021.xml · derivative · entry 2 Jodar Luis · CIK 0002151661 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,254 Underlying: Common Stock · 88,254 shares Expires 2036-09-04 F2 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 21:40 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 52,632 | $0.00 | $0.00 |
DisclosureSEC source: 0002151661-26-000004 · wk-form4_1788990021.xml · nonDerivative · entry 1 Jodar Luis · CIK 0002151661 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,632 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.